A clinical study of urinary NMP22 in urinary epithelial cancer

Journal of the Medical Society of Toho University

Volumn 51, Issue 6, 2004, Pages 332-338

  Takeuchi, Yasuhara ^a   Sawada, Yoshitomo ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Tumor marker; Urinary epithelial cancer; Urinary NMP22

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; TUMOR MARKER;

ADULT; ARTICLE; BENIGN TUMOR; BLADDER CANCER; CANCER INVASION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE CONTROL; EARLY DIAGNOSIS; ERYTHROCYTE; FEMALE; HUMAN; KIDNEY PELVIS CANCER; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PROGNOSIS; TUMOR VOLUME; URETER CANCER; URINE CYTOLOGY; URINE LEVEL;

EID: 17044425065     PISSN: 00408670     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. The Japanese Urological Association, The Japanese Society of Pathology (Eds): General Rule for Clinical and Pathological Studies on Bladder Cancer (2nd ed.) 101 p. Kanehara, Tokyo, 1993 (J)
2. Zippe C, Pandrangi L, Agarwal A: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 161: 62-65, 1999
3. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, Koiso K, Kobayashi M, Koyama A, Takahashi T: Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 31: 163-168, 1997
4. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, Lange P, Messing E, Pasciak RM, Reservitz GB, Rukstalis DB, Sarosdy MF, Stadler WM, Thiel RP, Hayden CL: Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 156: 363-367, 1996
5. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, Fritsche HA, McDougal WS: Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 159: 394-398, 1998
6. Miyoshi Y, Matsuzaki J, Miura T: Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma. Acta Urol Jpn 47: 379-383, 2001 (J)
7. Kurokawa S, Morita T, Muraishi O, Tokue A: Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer. Acta Urol Jpn 47: 247-250, 2001 (J)
8. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ: Prognostic markers in bladder cancer: A contemporary review of the literature. J Urol 160: 645-659, 1998
9. Akaza H, Koiso K, Kotake T, Matsumura Y, Isaka S, Machida T, Obata K, Ohashi Y, Ohe H, Ohi Y, Shimazaki J, Tashiro K, Ueda T, Kagawa S, Niijima T: Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: Experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother Pharmacol 30: S15-20, 1992